IBDEI0PF ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12543,2)
 ;;=^87693
 ;;^UTILITY(U,$J,358.3,12544,0)
 ;;=436.^^87^819^74
 ;;^UTILITY(U,$J,358.3,12544,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12544,1,4,0)
 ;;=4^436.
 ;;^UTILITY(U,$J,358.3,12544,1,5,0)
 ;;=5^Stroke,Acute Ill Defined
 ;;^UTILITY(U,$J,358.3,12544,2)
 ;;=^2710
 ;;^UTILITY(U,$J,358.3,12545,0)
 ;;=451.9^^87^819^75
 ;;^UTILITY(U,$J,358.3,12545,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12545,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,12545,1,5,0)
 ;;=5^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,12545,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,12546,0)
 ;;=446.6^^87^819^76
 ;;^UTILITY(U,$J,358.3,12546,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12546,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,12546,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpu
 ;;^UTILITY(U,$J,358.3,12546,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,12547,0)
 ;;=435.9^^87^819^77
 ;;^UTILITY(U,$J,358.3,12547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12547,1,4,0)
 ;;=4^435.9
 ;;^UTILITY(U,$J,358.3,12547,1,5,0)
 ;;=5^Transient Ischemic Attack
 ;;^UTILITY(U,$J,358.3,12547,2)
 ;;=^21635
 ;;^UTILITY(U,$J,358.3,12548,0)
 ;;=455.6^^87^819^58
 ;;^UTILITY(U,$J,358.3,12548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12548,1,4,0)
 ;;=4^455.6
 ;;^UTILITY(U,$J,358.3,12548,1,5,0)
 ;;=5^Hemorrhoids
 ;;^UTILITY(U,$J,358.3,12548,2)
 ;;=^123922
 ;;^UTILITY(U,$J,358.3,12549,0)
 ;;=403.90^^87^819^34
 ;;^UTILITY(U,$J,358.3,12549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12549,1,4,0)
 ;;=4^403.90
 ;;^UTILITY(U,$J,358.3,12549,1,5,0)
 ;;=5^HTN w/ CKD I-IV,Unspec
 ;;^UTILITY(U,$J,358.3,12549,2)
 ;;=^334272
 ;;^UTILITY(U,$J,358.3,12550,0)
 ;;=271.3^^87^820^10
 ;;^UTILITY(U,$J,358.3,12550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12550,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,12550,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,12550,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,12551,0)
 ;;=251.2^^87^820^28
 ;;^UTILITY(U,$J,358.3,12551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12551,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,12551,1,5,0)
 ;;=5^Hypoglycemia Nos
 ;;^UTILITY(U,$J,358.3,12551,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,12552,0)
 ;;=257.2^^87^820^29
 ;;^UTILITY(U,$J,358.3,12552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12552,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,12552,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,12552,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,12553,0)
 ;;=253.2^^87^820^32
 ;;^UTILITY(U,$J,358.3,12553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12553,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,12553,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,12553,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,12554,0)
 ;;=278.00^^87^820^39
 ;;^UTILITY(U,$J,358.3,12554,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12554,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,12554,1,5,0)
 ;;=5^Obesity (2nd dx only)
 ;;^UTILITY(U,$J,358.3,12554,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,12555,0)
 ;;=278.01^^87^820^38
 ;;^UTILITY(U,$J,358.3,12555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12555,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,12555,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,12555,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,12556,0)
 ;;=250.80^^87^820^9
 ;;^UTILITY(U,$J,358.3,12556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12556,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,12556,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,12556,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,12557,0)
 ;;=250.00^^87^820^4
 ;;^UTILITY(U,$J,358.3,12557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12557,1,4,0)
 ;;=4^250.00
